What if cancer cells could be re-engineered to turn against their own kind?
A new study in Science Translational Medicine, led by researchers at Brigham and Women’s Hospital, leverages the power of gene editing to take a critical step toward using cancer cells to kill cancer. The team reports promising results in preclinical models across multiple types of cancer cells, establishing a potential roadmap toward clinical translation for treating primary, recurrent and metastatic cancer.
“This is just the tip of the iceberg,” said corresponding author Khalid Shah MS, PhD, director of the Center for Stem Cell Therapeutics and Imaging (CSTI) in the BWH Department of Neurosurgery and faculty at Harvard Medical School and Harvard Stem Cell Institute (HSCI). “Cell-based therapies hold tremendous promise for delivering therapeutic agents to tumors and may provide treatment options where standard therapy has failed. With our technique, we show it is possible to reverse-engineer a patient’s own cancer cells and use them to treat cancer. We think this has many implications and could be applicable across all cancer cell types.”
The new approach capitalizes on cancer cells’ self-homing ability – the process in which cancer cells can track the cells of their kind that have spread within the same organ or to other parts of the body. Harnessing this power could overcome drug delivery challenges, helping get therapeutics to tumor sites that may otherwise be difficult to reach.
The team developed and tested two techniques to harness the power of cancer cells. The “off the shelf” technique used pre-engineered tumor cells that would need to be matched to a patient’s HLA phenotype (essentially, a person’s immune fingerprint). The “autologous” approach used CRISPR technology to edit the genome of a patient’s cancer cells and insert therapeutic molecules. These cells could then be transferred back into the patient.
To test both approaches, the team used mouse models of primary and recurrent brain cancer and breast cancer that has spread to the brain. The team saw direct migration of engineered cells to the sites of tumors and found evidence that the engineered cells specifically targeted and killed recurrent and metastatic cancer in the mice. The researchers report that the treatment increased the survival of the mice. Engineered cells were equipped with a “kill switch” that could be activated after treatment – PET imaging showed that this kill switch worked to eliminate the cells.
“Our study demonstrates the therapeutic potential of using engineered tumor cells and their self-homing properties for developing receptor-targeted therapeutics for various cancers,” said Shah.
The Latest on: Engineered cancer cells
via Google News
The Latest on: Engineered cancer cells
- Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapyon August 14, 2019 at 2:18 pm
Thus, engineered CBD-SA could be a versatile and ... translation to cancer therapy as an antitumor drug carrier. MMTV-PyMT cells were obtained from spontaneously developed breast cancer in FVB-Tg ...
- Fate Therapeutics Announces Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cellson August 14, 2019 at 6:53 am
engineered, homogeneous cell products that can be administered in repeat doses to mediate more effective pharmacologic activity, including in combination with cycles of other cancer treatments.
- Characterizing the genetic heterogeneity of murine breast cancer modelson August 13, 2019 at 6:23 am
To translate these findings into new treatments, investigators use model systems, including genetically engineered mouse models (GEMMs ... COL1A/CHAD amplified human BT-474 breast cancer cell line.
- Heat Biologics on go with early-stage study of cancer doublet therapy; shares up 12% premarketon August 12, 2019 at 10:12 am
Enrollment should start in Q4. HS-130 is an off-the-shelf genetically modified cell line engineered to stimulate the immune system against cancer. HS-110 is also an immune system-stimulating ...
- SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lineson August 12, 2019 at 2:17 am
We highlight the relevance of SMARCA4 as a drug target in esophageal cancer using an engineered ESCC cell model harboring a SMARCA4 allele amenable to targeted proteolysis and identify ...
- ‘Bone in a dish’ opens new window on cancer initiation, metastasis, bone healingon August 11, 2019 at 11:26 am
The bone-like engineered structure creates a microenvironment ... When the researchers injected prostate cancer cells nearby, they found that tumor growth was three times higher in the mice ...
- Lion TCR and Liaoning-Dalian Lvshun District Government to Develop Research and Manufacturing Facilities for Cancer Cell Therapieson August 8, 2019 at 7:35 pm
Ltd., a clinical-stage Biotech company focused on development of innovative engineered T cell immunotherapy against viral-related cancer and chronic Hepatitis B infection, announced on 29 July ...
- Cancer therapy returns to original target: HIVon August 8, 2019 at 11:24 am
The immune strategy has risks, but it builds on increasingly popular cancer treatments with T cells engineered to have surface proteins, called chimeric antigen receptors (CARs), that can recognize ...
- Medicare boosts CAR-T cancer therapies with expanded coverageon August 8, 2019 at 6:45 am
Medicare and Medicaid will cover CAR-T cell therapies nationally, a decision that helps address, but doesn't fully solve, the reimbursement challenges that have hampered uptake of the pricey cancer ...
via Bing News